Travere Therapeutics (TVTX) stock is in focus as the company inks a licensing deal worth up to $1.1B with China’s Everest ...

June 2 (Reuters) - Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest ...

The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the ...

Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic. The deal, ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization ...

This comprehensive health news summary covers significant developments in the pharmaceutical and healthcare sectors.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Travere Therapeutics (TVTX) and Glaukos (GKOS) with bullish sentiments. According to TipRanks.com, Rama ...

Travere Therapeutics Inc, a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease, announced ...

Less than two months after winning FDA approval for a second indication for Filspari (sparsentan), Travere Therapeutics Inc. added to its rare kidney disease pipeline by exclusively licensing ...

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest Medicines to ...